Michael Paul Lewis
  • Research Assistant I, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas 75390
  • Cancer Biology


Bachelor of Science in Biological Chemistry, University of Texas at Arlington, 2016


Chiang laboratory has had a long-time interest in understanding the mechanisms of transcription and gene regulation in mammalian cells using initially cell-free systems reconstituted with purified gene-specific transcription factors, general cofactors, and components of general transcription machinery to recapitulate transcriptional events in vitro.

Mechanistic studies based on cell-free transcription systems with DNA and chromatin templates are further evaluated in vivo by chromatin immunoprecipitation (ChIP), RT-PCR, reporter gene assay, co-immunoprecipitation (co-IP), nucleosome mapping, siRNA/shRNA knockdown, and CRISPR-Cas9 knockout using different types of cultured cells.

Recently, we have also adapted conditional knockout and transgenic knock-in mice to investigate the functional role of bromodomain-containing protein 4 (BRD4) using both xenograft and syngenic cancer models. In addition, patient-derived xenografts (PDX's) and organoids are used to evaluate BRD4 protein isoforms in cancer initiation and progression.

Our goals are to elucidate the general principles underlying gene activation and repression in mammalian cells and their associated viruses, in particular, DNA tumor viruses such as human papillomaviruses (HPV's).

The application of reconstituted chromatin transcription systems and HPV and cancer models has significantly advanced our mechanistic understanding of eukaryotic gene transcription and chromatin dynamics.

Our research is broadly categorized in the following six areas:

1.) Role of General Human Transcription Factors and Cofactors in Eukaryotic Transcription
2.) Transcriptional Regulation and DNA Replication in Human Papillomaviruses (HPV's)
3.) Post-Translational Modification
4.) Bromodomain-Containing Protein 4 (BRD4)
5.) BRD4-Regulated Transcription Programs and Cancer Pathways
6.) Therapeutics Targeting Phospho-BRD4

Laboratory URL:


Breast Cancer, Bromodomain-Containing 4 (BRD4), and Triple-Negative Breast Cancer (TNBC)


1. Lewis, M. P., Wu, S. Y. and Chiang, C. M. (2022). Conditional Human BRD4 Knock-In Transgenic Mouse Genotyping and Protein Isoform Detection. Bio-protocol 12(7): e4374. DOI: 10.21769/BioProtoc.4374.

2. Lewis, M. (2022). Fluoroquinolone Toxicity - From Mysterious Internet Illness to My New Reality: A Memoire of My Bout with Levofloxacin. Stimulus: A Medical Humanities Journal, 2, 47. DOI: 10.32855/Stimulus.2022.02.020.